Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

Several research analysts have recently issued reports on CPRX shares. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $35.00 to $31.50 in a research note on Thursday, May 28th.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.49 on Thursday. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. The business’s 50-day moving average price is $31.40 and its 200-day moving average price is $27.51. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Convergence Investment Partners LLC increased its stake in shares of Catalyst Pharmaceuticals by 106.8% in the first quarter. Convergence Investment Partners LLC now owns 75,682 shares of the biopharmaceutical company’s stock valued at $1,874,000 after buying an additional 39,092 shares during the period. Globeflex Capital L P lifted its stake in shares of Catalyst Pharmaceuticals by 54.2% in the first quarter. Globeflex Capital L P now owns 450,580 shares of the biopharmaceutical company’s stock worth $11,156,000 after acquiring an additional 158,372 shares during the period. WINTON GROUP Ltd lifted its stake in shares of Catalyst Pharmaceuticals by 546.7% in the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock worth $8,251,000 after acquiring an additional 298,862 shares during the period. Merit Financial Group LLC bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $654,000. Finally, Wakefield Asset Management LLLP bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $1,203,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).